Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6271472 | 0.85 | ALOX5 (0.55) | ESR2KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL27642331 | 0.85 | SLC6A9 (0.43) | ESR2SLC6A9KDM4EMEN1USP2 | |
| SCHEMBL4337657 | 0.80 | SLC6A9 (0.43) | ESR2SLC6A9KDM4EMEN1ALDH1A1 | |
| SCHEMBL7561256 | 0.80 | ALOX5 (0.61) | ESR2KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL4343066 | 0.78 | SLC6A9 (0.52) | SLC6A9 | |
| SCHEMBL4338534 | 0.78 | HAO1 (0.39) | SLC6A9MEN1ALDH1A1LMNAHSP90AA1 | |
| SCHEMBL4337764 | 0.78 | HSD17B10 (0.59) | SLC6A9MEN1ALDH1A1HSP90AA1HPGD | |
| SCHEMBL4334288 | 0.78 | SLC6A9 (0.62) | ESR2SLC6A9 | |
| SCHEMBL4330280 | 0.75 | MAOA (0.38) | SLC6A9 | |
| SCHEMBL15190516 | 0.73 | ALOX5 (0.61) | ESR2KDM4EMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612068-B2 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| CN-100439330-C | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | LUNDBECK & CO AS H (DK) | 2008-12-03 | — | — | CN | disclosed |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| CN-1780815-A | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | LUNDBECK & CO AS H (DK) | 2006-05-31 | — | — | CN | disclosed |
| EP-1622868-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096761-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | TYR, TPST2, COMT | ESR2 840/4885SLC6A9 2305/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.